Deloitte January 17, 2019
Jeff Morgan

The growing importance of real world evidence and value-based contracting programs

As the cost of health care continues to rise, life sciences companies are facing mounting pricing pressure and a growing need to continuously demonstrate the value of their products in a real-world population. These market forces are driving more and more life sciences companies to invest in new capabilities with the goal of harnessing the power of real world data (RWD) and changing how value is both demonstrated and rewarded.

Real world evidence (RWE) is evidence generated outside of a controlled clinical trial setting about a product’s usage, potential benefits, and risks. What makes it so valuable is that it is based on the analysis of RWD that is...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Insurance, Payment Models, Pharma, Provider, Technology, Trends, Value Based
Understanding CMS’ AHEAD Model: Medicare Hospital Global Budget Design and Implications
APG’s Susan Dentzer: the Value-Based World Is Steaming Ahead
How extending virtual options can drive value-based care
Health system C-suites eye value-based care roles
Incentivizing Provider Engagement for Improved Value-Based Outcomes

Share This Article